Avai Bio (AVAI) EBIAT (2018 - 2024)
Avai Bio's EBIAT history spans 6 years, with the latest figure at -$4.0 million for Q1 2024.
- For Q1 2024, EBIAT fell 590.05% year-over-year to -$4.0 million; the TTM value through Mar 2024 reached -$6.6 million, down 1788.53%, while the annual FY2025 figure was -$1.1 million, 46.34% up from the prior year.
- EBIAT for Q1 2024 was -$4.0 million at Avai Bio, down from -$1.8 million in the prior quarter.
- Across five years, EBIAT topped out at $417163.0 in Q4 2020 and bottomed at -$4.0 million in Q1 2024.
- The 4-year median for EBIAT is -$10350.0 (2020), against an average of -$530884.8.
- The largest annual shift saw EBIAT skyrocketed 4203.92% in 2020 before it crashed 1752.06% in 2023.
- A 4-year view of EBIAT shows it stood at $417163.0 in 2020, then plummeted by 73.52% to $110471.0 in 2022, then plummeted by 1752.06% to -$1.8 million in 2023, then plummeted by 116.63% to -$4.0 million in 2024.
- Per Business Quant, the three most recent readings for AVAI's EBIAT are -$4.0 million (Q1 2024), -$1.8 million (Q4 2023), and -$399621.0 (Q3 2023).